The field of multivalent glycosidase inhibition and carbohydrate‐protein interactions is at the forefront of chemical biology and medicinal chemistry. Researchers are developing synthetic systems that ...
On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter Positive topline del-zota data further supports ...
SAN DIEGO, Sept. 10, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback